Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents.

Yuasa S, Yamaguchi H, Nakanishi Y, Kawaminami S, Tabata R, Shimizu N, Kohno M, Shimizu T, Miyata J, Nakayama M, Kishi J, Toyoda Y, Nishioka Y, Tani K.

J Med Invest. 2013;60(1-2):77-90.

2.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

3.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140. Review.

4.

Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.

Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, Marie Bartels E.

Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6. Review.

PMID:
23838092
5.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
6.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.

Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Review.

7.

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. doi: 10.1002/14651858.CD007848.pub2. Review.

PMID:
19821440
8.

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.

Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T.

Scand J Rheumatol. 2007 Nov-Dec;36(6):411-7. Review.

PMID:
18092260
9.

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.

Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M.

PLoS One. 2012;7(1):e30275. doi: 10.1371/journal.pone.0030275. Epub 2012 Jan 17. Review.

10.

[Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].

Pérez Pampín E, Gómez-Reino Carnota JJ.

Med Clin (Barc). 2008 Feb 16;130(5):179-87. Review. Spanish.

PMID:
18341834
12.

[Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].

Amano K.

Nihon Naika Gakkai Zasshi. 2011 Oct 10;100(10):2966-71. Review. Japanese. No abstract available.

PMID:
22175139
13.

ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature.

Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G.

Arthritis Res Ther. 2009;11(6):R163. doi: 10.1186/ar2848. Epub 2009 Nov 3. Review.

Supplemental Content

Support Center